U.S. Markets open in 7 hrs 31 mins

Zalicus completes patient enrollment in two Z160 phase 2 studies

Zalicus announced that it has completed patient enrollment in two Phase 2 clinical studies of Z160 for chronic neuropathic pain indications including lumbosacral radiculopathy and postherpetic neuralgia. Top-line results of both studies are expected in Q4. Z160 is a first-in-class, oral, state-dependent, selective N-type calcium channel blocker in development for chronic neuropathic pain.